Zhou Jia-Bin, Qian Ling-Ling, Wu Dan, Wang Ru-Xing
Department of Cardiology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, 214023 Wuxi, Jiangsu, China.
Rev Cardiovasc Med. 2024 Apr 1;25(4):127. doi: 10.31083/j.rcm2504127. eCollection 2024 Apr.
Atrial fibrillation (AF) is one of the most common cardiac arrhythmias, with its diagnosis being closely tied to higher rates of cardiovascular morbidity and mortality. AF is associated with a range of dangerous complications including stroke and heart failure, making it a key driver of healthcare spending and a major threat to global public health. The precise mechanisms that govern AF incidence and the onset of related complications, however, remain uncertain. Ferroptotic cell death has been the focus of rising interest in the cardiac arrhythmias, and there is recent evidence supporting a role for atrial ferroptosis as a mediator of AF development. Interventional strategies focused on ferroptotic activity, such as novel ferroptosis inhibitors, have also shown promise as a means of protecting against AF through their ability to reduce iron overload. In this review, we provide a summary of the proposed mechanisms whereby ferroptosis contributes to the pathophysiology of AF and their therapeutic implications.
心房颤动（AF）是最常见的心律失常之一，其诊断与心血管疾病发病率和死亡率的升高密切相关。AF与一系列危险并发症相关，包括中风和心力衰竭，使其成为医疗保健支出的关键驱动因素以及对全球公共卫生的重大威胁。然而，控制AF发病率和相关并发症发生的精确机制仍不确定。铁死亡细胞死亡一直是心律失常领域日益受到关注的焦点，最近有证据支持心房铁死亡作为AF发展的介导因素发挥作用。专注于铁死亡活性的干预策略，如新型铁死亡抑制剂，也已显示出有望通过减少铁过载来预防AF。在本综述中，我们总结了铁死亡导致AF病理生理学的潜在机制及其治疗意义。
